Salarius Pharmaceuticals Receives FDA Clearance Of SP-3164 Investigational New Drug Application To Begin A Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
Portfolio Pulse from Benzinga Newsdesk
Salarius Pharmaceuticals has received FDA clearance for its Investigational New Drug Application for SP-3164. The company will begin a Phase 1 clinical trial in patients with relapsed/refractory Non-Hodgkin Lymphoma. The trial will assess the safety and preliminary efficacy of SP-3164, with patient dosing expected to begin in 2H 2023.
July 11, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Salarius Pharmaceuticals' FDA clearance for SP-3164 could potentially boost investor confidence in the company. However, the actual impact on the stock will depend on the results of the Phase 1 trial.
FDA clearance for a new drug is a positive development for a pharmaceutical company as it allows the company to proceed with clinical trials. This could boost investor confidence in the company's research and development capabilities. However, the actual impact on the stock will depend on the results of the Phase 1 trial, which are yet to be determined.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100